U.S. FDA approves Amgen heart failure drug

April 15 (Reuters) - U.S. health regulators on Wednesday approved Amgen Inc's Corlanor to treat patients with chronic heart failure, giving the world's largest biotechnology company its first cardiovascular medicine product.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.